Mateon Therapeutics Inc (OTCMKTS:MATN) shares passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $0.18 and traded as high as $0.19. Mateon Therapeutics shares last traded at $0.18, with a volume of 770,525 shares traded.
Separately, ValuEngine raised Mateon Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday, March 3rd.
The business’s fifty day moving average is $0.17 and its two-hundred day moving average is $0.18.
Mateon Therapeutics, Inc, a clinical-stage biopharmaceutical, focuses on developing small molecule injectable drugs for the treatment of cancer. It is developing CA4P, an immuno-oncology agent that stimulates the immune system against the tumor; and OXi4503 for the treatment of relapsed/refractory acute myeloid leukemia.
Recommended Story: When can a hold rating present a buying opportunity?
Receive News & Ratings for Mateon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mateon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.